Faith Kibutu
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Intracerebral and Subarachnoid Hemorrhage Research
- Long-Term Effects of COVID-19
Papers in
-
- COVID-19 Clinical Research Studies 10
- Genetics 6
- Genetic Associations and Epidemiology 6
- Journals
- The Lancet (7 papers)Nature (5 papers)Nature Cancer (2 papers)EClinicalMedicine (1 paper)The Lancet Neurology (1 paper)
- Partner nations
- United KingdomSwedenVietnam
In The Last Decade
Faith Kibutu
23 papers receiving 3.1k citations
Faith Kibutu's Hit Papers
Peers
Comparison fields: 5 of 76
- Infectious Diseases 1.3k
- Neurology 227
- Applied Microbiology and Biotechnology 30
- Genetics 299
- Oncology 110
Countries citing papers authored by Faith Kibutu
This map shows the geographic impact of Faith Kibutu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faith Kibutu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faith Kibutu more than expected).
Fields of papers citing papers by Faith Kibutu
This network shows the impact of papers produced by Faith Kibutu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faith Kibutu. The network helps show where Faith Kibutu may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | 2019 | 149 | |
| 9 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 10 | 2022 | 93 | |
| 11 | 2023 | 84 | |
| 12 | 2019 | 75 | |
| 13 | 2020 | 75 | |
| 14 | 2023 | 60 | |
| 15 | 2021 | 51 | |
| 16 | 2021 | 34 | |
| 17 | 2021 | 26 | |
| 18 | 2023 | 25 | |
| 19 | 2024 | 24 | |
| 20 | 2024 | 8 |
About Faith Kibutu
Faith Kibutu is a scholar working on Infectious Diseases, Genetics, Neurology, Oncology and Immunology, having authored 24 papers that have together received 3.3k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (10 papers), Genetic Associations and Epidemiology (6 papers), Intracerebral and Subarachnoid Hemorrhage Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), T-cell and B-cell Immunology (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Neurology (227 citations), Applied Microbiology and Biotechnology (30 citations), Genetics (299 citations) and Oncology (110 citations). Faith Kibutu has collaborated with scholars based in United Kingdom, Sweden and Vietnam. Their work appears in journals such as The Lancet, Nature, Nature Cancer, EClinicalMedicine and The Lancet Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.